Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH607 in Major Depressive Disorder
NCT07101120Phase 2Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KH607 in major depressive disorder (MDD), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Started Mar 2025; status: completed.
02
Drugs
KH607
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07101120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101120.